Psychedelic Weekly Headlines | September 30

September 30, 2022
Headlines

Helping investors discover, understand, and stay up-to-date on market news and investment opportunities within the Psychedelic industry.


Markets

Performance of psychedelic public companies this past week.


Company News

Silo Wellness ($SILO | $SILFF) entered into a definitive agreement to acquire Dyscovry Science and their psilocybin pharmaceutical biosynthesis and research portfolio. Dyscovry intends to develop a biotechnological process for the production of psilocybin and their potentially novel molecule derivatives. Press Release          

Tryp Therapeutics ($TRYP | $TRYPF) filed two new provisional patent applications for the use of psilocybin for the treatment of patients with fibromyalgia and for crystalline forms of TRP-8803. Tryp is preparing for a Phase IIa clinical trial in collaboration with the University of Michigan to investigate safety and efficacy of psilocybin-assisted therapy among patients with fibromyalgia. Press Release          

Psyence Group ($PSYG | $PSYGF) successfully exported medical grade psilocybin mushrooms to Psilo Pharma through their research partner in Portugal. Psyence operates one of the first federally licensed commercial psilocybin production facilities in the world. Press Release          

Cybin ($CYBN) entered into an agreement with Mindset Pharma to acquire an exclusive license to a novel catalog of psychedelic-based compounds. Press Release

Mind Medicine ($MNMD | $MMED) announced a proposed public offering of 7,058,823 common shares with accompanying warrants. The combined offering price of each common share and warrant is $4.25, with gross proceeds from the offering expected to be approximately $30 million. Press Release

atai Life Sciences ($ATAI) received regulatory and ethics approvals required to initiate participant enrollment for their Phase I study of EMP-01, a MDMA derivative being developed as a potential treatment of PTSD and other indications. Press Release          

Wellbeing Digital Sciences ($MEDI | $KONEF) subsidiary KGK Sciences opened their new Clinical Research Center in London, Ontario, with the aim to accelerate their clients’ research and drug development needs in the nutraceutical, cannabinoid, hemp and psychedelic space. Press Release          

Core One Labs ($COOL | $CLABF) entered into a Letter of Intent with Medelys Laboratories International to manufacturing their proprietary psychedelic active pharmaceutical ingredient products. Press Release          


Media

Fortune: What Happens To Your Brain On Psychedelics?          

Nature: Outlook on Psychedelic Medicine          

The Economist: The Psychedelic Renaissance In Medicine          

Filter: First US Pilot Program for MDMA and Psilocybin Treatment Moves Forward          

Politico: Navigating the Highs and Lows of Psychedelic Therapies          


Be the first to see new company features, exclusive interviews and breaking news in the psychedelic markets. Subscribe now.

Always do your own research and make your own investment decisions. This is not a solicitation to purchase or sell securities. Psychedelic Finance is not a registered investment advisor and does not purport to provide investment advice, whether implied or otherwise. Psychedelic Finance does not independently verify the accuracy or the truth of the statements or representations made by issuers. This message is meant for information and educational purposes only and Psychedelic Finance does not intend for this information to be used to inform an investment decision.